阿帕替尼单药治疗晚期恶性肿瘤的疗效及不良反应分析

Efficacy and safety of apatinib monotherapy in patients with advanced malignancies

目的:分析阿帕替尼(apatinib,YN968D1)单药治疗晚期恶性肿瘤的疗效及不良反应。方法:检索Embase、PubMed、中国知网数据库,使用RStudio-3.5.1对纳入资料进行累积率的统计分析。结果:共检出文献1260篇。根据纳入及排除标准,最终纳入194篇,包括118篇中文文献和76篇英文文献,总病例数为6740例。结果显示,阿帕替尼单药治疗晚期胃癌、肺癌、乳腺癌、大肠癌、肉瘤的6个月PFS累积生存率分别为15%、26%、31%、24%、50%;单药治疗晚期肺癌、乳腺癌、大肠癌、肉瘤的12个月OS累积生存率分别为27%、38%、30%、45%。阿帕替尼常见不良反应有高血压、手足综合征和蛋白尿,累积发生率分别为39%、32%、28%。结论:阿帕替尼用于晚期恶性肿瘤的二线及以上治疗,具有客观有效性及安全性。

Objective:To evaluate the efficacy and safety of apatinib(apatinib,YN968D1)monotherapy in advanced malignant tumors with second-line or above treatments failure.Methods:Embase,PubMed and CNKI databases were searched.RStudio-3.5.1 was used to conduct statistical analysis on the pooled rate of the included data.Results:1260 literatureswere searched and 194 literatures were finally included,involving 118 literatures in Chinese and 76 literatures in English.The number of total cases in this study was 6740.The results showed that the pooled survival ratio of 6-month PFS was 15%in gastric cancer,26%in lung cancer,31%in breast carcinoma,24%in colorectal cancer and 50%in sarcoma respectively.The pooled survival ratio of 12-month OS was 27%in lung cancer,45%in sarcoma,38%in breast carcinoma,30%in colorectal cancer respectively.The common AEs were hypertension,hand-foot syndrome and proteinuria,with a pooled incidence ratio of 39%,32%and 28%respectively.Conclusion:Apatinib was effective and safe in treating advanced malignancies that had failed second-line or above treatments.